Unknown PHASE4 INTERVENTIONAL NCT00226473

Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma

Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy (CVD-Protocol) in the Second-Line Therapy of Distant Metastasized Malignant Melanoma

Sponsor: Dermatologic Cooperative Oncology Group

Conditions Metastatic Melanoma

Interventions Cisplatin, Vindesine, Dacarbazine (drugs)

Updated 6 times since 2017 Last updated: Jun 20, 2006 Started: Sep 30, 2001 Completion: Sep 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Metastatic Melanoma and is currently ongoing. Dermatologic Cooperative Oncology Group leads this study, which shows 6 recorded versions since 2001 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE4
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE4

First recorded

Sep 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dermatologic Cooperative Oncology Group

Data source: Dermatologic Cooperative Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Berlin, Germany , Buxtehude, Germany , Erfurt, Germany , Frankfurt am Main, Germany , Hildesheim, Germany , Homburg, Germany , Jena, Germany , Kiel, Germany , Lübeck, Germany , Magdeburg, Germany and 2 more locations